BioPharma Resources

Drug Trial Radar · NCT04893187

A Phase 1 Study of SSS17 in Healthy Subjects.

A Phase 1 Study to Evaluate the Tolerance, Safety, Pharmacokinetics and Pharmacodynamics of Oral Administration of SSS17 in Chinese Healthy Adult Subjects With Single and Multiple Dose Escalation and the Effect of Food on the Pharmacokinetics of SSS17.

Last checked: Nov 19, 2026Latest source record: Jan 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

76

Planned (sponsor's estimate)

Start

Jul 26, 2021

Primary completion

Dec 31, 2022

Study completion Jun 30, 2023

Sponsor

Sponsor type
Industry
Collaborators
Fifth Affiliated Hospital of Guangzhou Medical University
First posted
May 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of single oral administration of 5 mg, 15 mg, 20 mg and 25 mg of SSS17 compared with placebo, and evaluate the efficacy, safety, tolerance, pharmacokinetics and pharmacodynamics of multiple oral administration of 15 mg and 20 mg of SSS17 compared with placebo. In addition, the study will assess the effect of food on the pharmacokinetics of SSS17.

Conditions

  • Anemia in Chronic Kidney Diseases

Interventions

  • SSS17Drug

    SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.

  • PlaceboDrug

    Matched placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: AEsTime frame: Baseline up to Days 15
  2. Part 1: Maximum plasma concentration (Cmax) of SSS17Time frame: Up to 336 hours post-dose
  3. Part 1: Area under the concentration-time curve (AUC) of plasma concentration of SSS17Time frame: Up to 336 hours post-dose
  4. Part 1: Time-to-Cmax (Tmax) of SSS 17Time frame: Up to 336 hours post-dose
  5. Part 1: Elimination terminal half-life (t1/2) of SSS17Time frame: Up to 336 hours post-dose
  6. Part 1: . Total amount of SSS17 excreted in urine over 72 hours (Ae0-72)Time frame: Up to 72 hours post-dose
  7. Part 1: Fraction of SSS17 excretion during each collection interval (Fe0-72)Time frame: Up to 72 hours post-dose
  8. Part 1: Renal clearance (CLR) of SSS17Time frame: Up to 72 hours post-dose
  9. Part 2: AEsTime frame: Up to Days 33 or 57
  10. Part 2: Steady state minimal concentration (Css_min) of SSS17Time frame: Up to Days 33 or 57
  11. Part 2: Steady state maximum concentration (Css_max) of SSS17Time frame: Up to Days 33 or 57
  12. Part 2: Steady state average concentration (Css_av) of SSS17Time frame: Up to Days 33 or 57
  13. Part 2: Area under the concentration-time curve of plasma concentration of SSS17 within the interval of administration after reaching steady state (AUC0-τ)Time frame: Up to Days 33 or 57
  14. Part 3: Maximum plasma concentration (Cmax) of SSS17Time frame: Up to Days 44
  15. Part 3: Area under the concentration-time curve (AUC) of plasma concentration of SSS17Time frame: Up to Days 44
  16. Part 3: Time-to-Cmax (Tmax) of SSS 17Time frame: Up to Days 44
  17. Part 3: Elimination terminal half-life (t1/2) of SSS17Time frame: Up to Days 44

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Fifth Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.